Intra-Cellular Therapies, Inc. announced a settlement with Sandoz Inc. regarding patent litigation involving their product CAPLYTA® (lumateperone). This litigation arose from Sandoz's attempt to ...

Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe ...

However, the reduction in AER observed after 2 months with irbesartan treatment is in accordance with the findings shown in the IRMA II after 3 months of therapy ( 30% for both studies), proving ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...